Recently, Endovastec™’s Minos™ Abdominal Aortic Stent-Graft and Delivery System (Minos™) was successfully implanted in the first clinical case at Baku Merkezi Hospital in Azerbaijan. The surgery was performed by Professor Kamuran Musayev and his vascular surgery team.
The patient was a 66-year-old male diagnosed with an infrarenal abdominal aortic aneurysm measuring approximately 84mm, with left-sided iliac artery stenosis confirmed by CT angiography. Professor Kamuran Musayev successfully performed the procedure using Minos™ by delivering the system through a femoral artery puncture and advancing it to the anchoring zone below the renal arteries. Postoperative imaging showed accurate positioning of Minos™, effective isolation of the diseased portion of the aneurysm, and no signs of leakage or displacement.
This marks the entry of Minos™ into its 16th country, following China, Greece, the United Kingdom, Poland, Germany, Brazil, Argentina, and others. To date, Minos™ has successfully treated over 6,000 patients worldwide with abdominal aortic diseases.
In the future, Endovastec™ will continue to dedicate itself to delivering high-quality and innovative products to more countries worldwide, aiming to bring well-being to patients with circulatory diseases across the globe.
Minos™ is designed for endovascular treatment of infrarenal abdominal aortic aneurysms. It is the new generation of Abdominal Aortic Stent-Graft and Delivery System developed by Endovastec™.1 Its outer sheath diameter is a reduced size of 14F, significantly minimizing the requirements for vascular access during surgery. The stent graft structure is designed in three segments, allowing for flexible assembly inside the body and maximum coverage of the diseased area. It has unique advantages in treating complex abdominal aortic aneurysms, particularly those with twisted necks, short necks, or narrowed access arteries.2
1.Data on File.
2.Fu W. The MinosTM Ultra-Low Profile Stent Graft in AAA Repair: A Prospective, Multicenter, Single-Arm Premarket Clinical Trial. Supplement to Endovascular Today Europe. 2023;11(2):1–16.